Synthetic heart graft patient reaches milestone:
This article was originally published in Clinica
CardioTech International says that the first recipient of its investigational synthetic coronary artery bypass graft, CardioPass, has reached the one-year mark. The female patient, who had been considered a "no option" patient because she had no usable mammary artery, received the implant in Brazil in August 2003. She is currently leading a normal life, is asymptomatic and has no cardiac pain, said the Wilmington, Massachusetts firm. Her blood pressure and EKG are also both normal. In addition, two further patients who received the implant last year are also leading normal lives. CardioPass is designed to obviate the need for vessel harvesting surgery. CardioTech estimates the annual worldwide market for the synthetic graft will be in excess of $1bn.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.